Biotech Movers

Quarter 3 2020

ALBO +44.76%
ALPN +134.98%
IMMU +97.99% (buyout from GILD)
INO +40.98% [ announced $71M funding from DOD for its experimental COVID19 vaccine]
ITCI +72.87%
MCRB +389.22%
MNTA +69.17% (buyout from JNJ)
TBIO +46.98% [ expanded partnership w/ Sanofi for the development of COVID19 vaccine]
BMRN -35.28% ( received CRL from FDA)
ICPT -39.73% (received CRL obeticholic CID)
TCDA -40.31%
Sell the Gap
No data found.
Reversal off Lows
No data found.

Quarter 2 2020

ARCT +35.27%
AXSM +24.35%
CAPR +252.70%
MGNX +230.92%
No data found.
Sell the Gap
No data found.
Reversal off Lows
No data found.

Quarter 1 2020

AGTC +122.84% (reported PH 1/2 XLRP)
No data found.
Sell the Gap
No data found.
Reversal off Lows
No data found.

Quarter 3 2019

CAPR +93.48% (Positive HOPE-2 trial)
No data found.
Sell the Gap
No data found.
Reversal off Lows
No data found.

Quarter 2 2019

ABIO +98.64% (P2B data published in ACC)
ADMA +24.32% (FDA approval)
AGN +25.36% (buyout by ABBV)
DMPI +140% (-49.75% next day on offering; rallies on clinical updates in ASCO)
GNCA +19.61% ( +110% in 2 days rally; GEN-009 presented at ASCO)
LJPC +92.48% (positive P2 study of LJPC-401)
MBIO +112.03% (clinical data update)
MBRX +168.47% (FDA fast track)
MRTX +31.58% ( rallies on AMGN P1 Kras data)
PETX +39.65% (buyout)
PHAS +30.18% (technical momentum)
PRVB +217.01% (Data published in NEJM)
SGMO +28.96% (clinical update)
SOLY +42.62% (FDA 510(k) Clearance for RAP device)
ACER -78.63% (CRL from FDA)
ADXS -31.36% ( secondary pricing at $4)
AMRX -35.98% (announces restructuring plan for $50M annual savings)
AVEO -29.02% (slump on stock sale)
BCRX -52.91% (announced result from P3 Apex- 2 trial)
CBAY -45.45% (data not significant compared to placebo)
HRTX -18.13% (FDA CRL)
IFRX -91.79% (failed data)
IMGN -32.06% (FDA recommends new P3 trial of mirvetuximab soravtansine)
NBRV -27.42% (FDA CRL)
OCUL -22.55% (P3 OTX-TP failed to meet primary endpoint)
SVRA -75.21% (failed P3 Imapala study primary efficacy endpoint)
SYRS -23.28% (offering)
ZGNX -22.93% (Refusal to file letter from FDA)
ZSAN -26.75% (offering)
Sell the Gap
ADXS-40% (from $10.80 to $6.51)
TGTX -14% (from $9.30 to $8.09)
VKTX (-18 reversal from $11.03-$9.97)
Reversal off Lows
No data found.

Quarter 1 2019

ACHV +84.36% (announces final data from cytisinicline study)
AKTX +224.18% (Positive FDA meeting for pre-IND)
ALDX +35.99% (postive topline P3)
ARQL +67.38% (earnings update)
ASND +74% (positive Phase 3 data)
ATOS +368.21% (FDA approval of Oral Endoxifen)
AXSM +161.22 (Meet P2 endpoints)
BPTH +160.46% (rally on clinical update on P2 PREXIGEBERSEN)
BPTH +223.29% (low floater)
CELG +20.69% (acquired by BMY)
CMTA +74.43% (BUYOUT)
DERM +84.36% (positive topline 2b)
EOLS +26% (FDA approved wrinkle drug)
IMDZ +309.86% ( acquired by Merck for $5.85/ share)
INSM +43.23% (drug sales update Arikayce)
LOXO +66.33% (LLY $8 B buyout)
MCRB +24.85% (Collaboration)
MGNX +130.42% (success P3 data)
NITE +66.09% (Buyout from BIIB)
ONCE +120.09% (BUYOUT)
PHAS +67.47% (P1 PB2452 data)
SAGE +42.68% (P3 succeeds)
TNDM +25.20% (earnings report beat)
ACIU -65.98% (discontinue P3)
BIIB -29.23% (discontinue P3 ENGAGE & EMERGE ALZ trials w/ Eisai)
CANF -31.00% (fail data)
GNMX -75.32% (AEVI-001 failed)
IMMU -26.42% (CRL from FDA)
LJPC -50.19% (sales missed expectation)
LXRX -22.60% (Adcom split decision for Sotagliflozin approval)
PETX -26.55% (Engaged Capital cut it stake)
PRTO -85.60% (negative data)
PT -68% (CF data)
REPH -34.05% (CRL from FDA)
SELB -21.03% (SEL-212 update)
SGMO -30.87% (SB-318 no clinical benefits)
SLDB -67.82% (muscular dystrophy data failed)
TYME -35.39% (SM-88 data)
VNDA -19.95% (filed complaint against FDA seeking to lift clinical hold on tradipitant)
Sell the Gap
No data found.
Reversal off Lows
No data found.

Quarter 4 2019

CNST +90.25% (ASH winner)
RETA +56.99% (record high;Part 2 portion of the MOXIe Phase 2 trial of omaveloxolone in patients with Friedreich's ataxia, or FA, met its primary endpoint)
RLMD +134.03% (record high; reports REL-1017 has rapid onset and sustained antidepressant efficacy with statistically significant differences compared to placebo on all efficacy measures)
ARQL -17.88% (ASH loser)
Sell the Gap
No data found.
Reversal off Lows
No data found.

Quarter 4 2018

AIMT +15.48% (rallies on DBVT withdrawal of Viaskin Peanut application)
ARNA +21.62% (License agreement with UTHR)
BHVN +25.39% (reported topline P3 trial of ZYDIS ODT)
CMTA +48.23% (NDA for Palovarotene)
CORI +53% (buyout by Gurnet Point Capital)
ECYT +50.39% (Buyout)
GBT +47.81 % (FDA accept AA)
NK +37.27% (announces results of haNK in novel cancer memory vaccine immunotherapy)
PTI +447.62% (positive preliminary from P1 study)
QURE +35.66% (dose confirmation AMT-061)
RVNC +19.47% (RT002 data and license agreement with Fosum Pharma)
TSRO +58.47% (buyout from GSK)
ABUS -33.99% (Update HBV development programs)
ADAP -30.11% (data update at ESMO)
ADRO -30.41% (data update)
ADVM -26.59% ( to discontinue lead asset ADVM -043)
AFMD -24.41% AFM11 (Patient death)
AMRN -32% (sell the news after REDUCE-IT data update)
CLSD -62.77% (failed phase 3)
DOVA -56.64%( 3 days sell off- launch of Doptelet is slower than expected & CEO changes)
DVBT -59.29% (withdraws Viaskin Peanut application)
IDRA -39.70% (ILLUMINATE-204 data)
IMDZ -50% (Discontinue P 3 SYNOVATE)
INFI -45.42% (Phase 1b data update at SITC)
MDXG -41.16% (delisting notification)
MNLO-39.57% (failed data)
ONCS -49.81% (preliminary KEYNOTE-695)
PBYI -48.01% (earnings sales disappointment)
SELB -33.36% (P2 SEL-212 data)
SGYP -69.28% (bankruptcy concerned)
SNNA -37.59% (SNA-120 data)
SPPI -38.79% (FDA did not grant BTD to Poziotinib for NSLC treatment)
SURF -47.50% ( reduces scope for CD47 program, accelerates SRF388IND)
TRVN -64.09% (FDA briefing docs)
Sell the Gap
AKBA -30% (high $10.06 to low $7.72)
MDGL -31% (High $190 to low $145.43, sell the news data)
MRNS -41% ( 5 days after the gap up)
PTLA -25% (High $25.00 to low $19.80)
VKTX -19% (high $13.78 to low $11.28. Sell the news data)
Reversal off Lows
ACRX +40% (two days reversal after FDA docs)

Quarter 3 2018

ACAD +26.56% (FDA find no safety issues in Nuplazid)
ACIU +38.28% ( rallies in sypathy of BIIB positive Alzheimer's news)
ADMP +50.00% (distribution agreement with Sandoz Inc)
AFMD +246.88% (collaboration news)
ALDX +34.85% (positive P2 dry eye data)
AMRN +314.72% (successful Phase 3 data)
ARQL +20.11% ( technical breakout)
ARWR +37.52% (ARO-HBV data)
AVXL +43.66% (initiate Phase 2b/3 clinical trial)
BIIB +19.63% ( rallies on positives of its Alzheimers drug data)
CRBP +53.62% (Expand compound focused)
GLMD +21.23% (Cantor $59 price target)
INSY +34.05% (FDA fast track Epinephrine nasal spray)
MNKD +89.09% (Collaboration with UTHR)
OBLN +52.00% (raise $10M in private placement)
PRQR +120.75% (Interim Phase 1/2 result)
PTGX +56.21% (Phase 2 Propel study)
REPH +26.49% (update FDA meeting IV meloxicam)
RETA +64.98% ( Positive results of Phase 2 bardoxolone methyl for CKD/ CARDINAL study)
SBBP +30.89% (Positive Phase 3)
TORC +49.50% (positive Phase 2 data)
VKTX +87.30% (succeed mid-stage study)
VTGN +37.50% (FDA fast track)
VXRT +88.85% (technical breakout)
ZGNX +20.30% (Phase 3 achieved endpoint)
ACOR -24.50 % (Court appeal denied for Ampytra patents)
AKCA -25.33% (CRL from FDA)
AVEO -24.21% ( TIVO P3 data readout moves to Q3)
BLPH -68.85% (DMC rec stopping P3)
CTIC -43.36% (Delayed data until 2Q 2019)
GEMP -52.04% (FDA asks for more data)
GERN -62.92% (discontinuation trial)
GTXI -92.27% (failed P2)
MDXG -38.50% (CEO, COO resigned)
MRSN -31.59% (clinical hold for XMT-1522 trial)
ONCE -27.83% (safety concerns for Hemophilia trial)
OVID -36.55% (Positive data, but investors questions)
PGNX -17.88% (P3 co endpoints met and misses)
SGMO -23.62% (16 week clinical SB-913 data)
SPPI -22.66% (Sell-off due to update Ponzi data)
TGTX -44.32% (DSMB cannot be conducted)
TSRO -23.55% (Disappointing earnings sales numbers)
VTL -98.85% (Failed P3 data)
ZYNE -24.09% (offering news)
Sell the Gap
TORC +13.4% (+28% initial spike on reports of P2a of TORC1
Reversal off Lows
ACIU +56% (Stock move with Biogen Inc Alzheimer's disease news)
SNNA -4.46% (-18.66% intraday low; 2 SNA-001 trials did not meet secondary endpoints)

Quarter 2 2018

ABEO +18.21% ($16.55 closing, in lieu of AVXS buyout)
ALNY +29% (Movers of 12 days straight gain)
ALXN +14.50% (Positive Phase 3)
ARMO +67.00% (Buyout from LLY)
AVGR +72.87% (FDA clearance on PAD device)
AVXS +81.57% ($210.46 closing,Buyout from NVS)
AXON +160% (Licensing agreement for OXB-102)
BLCM +20.29% (Clinical hold lifted studies BPX-501)
BOLD +14.76% ($32.26 closing, in lieu w/ AVXS buyout)
CARA +42.76% (joint venture with Fresenius)
CLBS +67.34% (technical breakout)
CLLS +25.38% (Pfizer 8% stake)
DCPH +47.86% (Target raised to $33 at JPMorgan)
EDAP +62.90% (received FDA clearance for Focal One)
EIGR +41.77% (expands license agreement with Merck)
GEMP +94.47% (positive INDIGO data)
GLMD +151.29% (Clinical data update)
HRTX +30.13% (positive topline data)
HTBX +94.86% (Low floater technical breakout)
INNT +41.54% (technical breakout)
KPTI +10.93% (Positive Phase 2 data)
MDGL +144.96% (MDL-3196 achieve endpoints)
MNOV +18.88% (P2 trial of MN-001 interim result)
OMER +23.31% (Earnings report reaction)
ONCE +13.37% ($70.36 closing, in lieu of AVXS buyout)
PFNX +31.15% ('positive' top-line PF70)
PTCT +27.72% (interim data FIREFISH study update)
PTCT -30.58% (negative mover from SRPT news)
PTLA +25.64% (Andexxa approved by FDA)
RIGL +16.72% (PDUFA date unchanged to April 17)
SLDB +46.36% (positive move from SRPT news)
SLS +150.72% (positive interim data from p2b NeuVax Trial)
SPPI +41.90% (update MD Anderson Phase 2 data of poziotinib)
SRPT +36.76% (preliminary positive gene therapy for DMD)
STDY +77.36% (buyout)
VBLT +39.53% (positive data MOSPD2 plaform)
VKTX +101.01% (Sympathy to MDGL data)
VLRX +76.27% (Glooko partner for V-Go SIM)
VSTM +31.39% (Poster presentation at EHA)
XBIO +103.90% (Low float technical move)
XLRN +42.79% (Luspatercept positive data)
ACAD -23.36% (report of deaths and Nuplazid, CNN report)
AKAO -24.76% (Adcom voted against BSI)
AKER -33.58% (withdraw its 510k FDA Application for PIFA Chlamydia)
AKRX -33.76% (Fresenius terminates merger)
ALKS -21.96% (FDA Refusal to File letter received for ALKS 5461)
AMRX -17.98% (earnings reaction*$15.01 closing)
ANIK -24.68% (earnings reaction)
ANIK -37.62% (CINGAL 16-02 did not achieve its primary endpoint)
AQXP -84.72% (cystitis drug fail)
ASNS -77.19% (discontinuation of Phase 2 ASN100)
BMY -7.79% ( sell off on NSCLC data, $54.08 closing)
CBIO -63.92% (slide on update CB2679d IX program)
CELG -4.47% (4/30* reaction on RTF for OZANIMOD could take up to 3 years* $87.10 closing)
CLDX -64.60% (P2b METRIC study did not meet primary endpoints)
CLSD -32.19% (Underwhelming 'postive' data )
CNAT -31.45% ($4.12 closing) Phase 2b trial of liver transplant patients misses primary endpoint
DERM -22.61% ( slump on Investor & Analyst day presentation, 5/24)
ESPR -35.11% (Safety concerns on data)
FLKS -75% (End two studies FLX-787)
INCY -22.93% (failed Phase 3 study ECHO-301 )
JNCE -33.66% (ICONIC data update)
JNCE -35.20% (underwhelming abstract)
LPTX -23.10% (Stock selling off after clinical data at AACR)
MACK -43.83% (discontinue pancreatic study)
MNLO -76.80% (failed Phase 2)
NBRV -16.57% (Company said data meets all primary endpoints)
NERV -9.56% (earnings reaction)
NKTR -41.32% (Update ASCO data NKTR-214)
NLNK -42.62% (Company review combo study after INCY & MRK failed study)
PBYI -20.67% (delayed data to 2h 2018)
PRTA -68.78% (discontinues NEOD001)
PTGX -22.38% (PTG-100 data dealyed 3Q 2018)
PTIE -71.51% (voted 14-3 against approval)
REPH -54.67% ( slumped on FDA CRL for IV Meloxicam)
SPHS -40.27% (discontinue study due to patient death)
VTVT -78.08% (Failed Phase 3 data)
Sell the Gap
CALA -2.36% (+17.3% intraday high; FDA fasttrack designation for CB-839)
CMTA -20.88% (+1.74% intraday; +6% premarket after Ph 2B data of Palovarotene treatement for FOP)
DVAX -21% (Gap up +16% on abstract data to red closed -4.56%)
RGNX +15.62% (+31% intraday high; $31.45 closing)
Reversal off Lows
BHVN +40% (reversal off low in 13 days after clinical update)
NKTR -7% (-19% intraday, dropped on BMY cancer data, $93.47 closing)
SELB +35% (reversal with four straight green days after data sell off)
VTVT +128.12% (Two days reversal move +43.25% and 84.87%)

Quarter 1 2018

ADMP +31.37% (Updates Symjepi commercialization plans, including seeking a commercial partner)
ALDR +17.37% ( Eptimezumab met primary endpoint in PROMISE 2 trial
AMAG +29.14% ( FDA approval of Amag Pharmaceuticals NDA for Makena)
ANAB +9.29% ( in lieu of DVBT move)
ANTH +43.79% ( Roth initiated w/ BUY $10 target; $2.43 closing)
APOP +37.78% (Successful transplant using ApoGraft
ARNA +28.68% (positive phase 2 reults from OASIS trial)
ARRY (+15.54%) OS data from P3 COLUMBUS trial
BLUE +10.63% ( in lieu of JUNO/ CAR- T acquisitions)
BOLD +14.86% (-23.32% after 2 days) (*positive data of 1st dose cohort of ASPIRO Ph1/2 of AT132, record high)
CALA +16.55% (Citi upgrades to BUY w/ $14 price target)
CCXI +39.42% (secures up to $100M in new capital commmitments
CHRS +30.22% (Closing at $11.85 after earning update)
CLSD +25.36% (3/6/18* 2nd day run* $12.95 closing)
CLSD +32.10% (Positive CLS-TA trial)
CRSP +14.90% ( upgraded by SunTrust and raised price target to $45 from $16)
DARE (+50.00) enters into license and collaboration agreement with SST
DVBT +25.74% ( FDA supports submission of Viaskin Peanut application)
GBT +19.07% ( FDA Breakthrough Therapy Designation for Voxelotor.)
HRTX +26.98% (Phase 3 success data HTX-011)
IMGN +18.35% ( 52 weeks high/ technical breakout)
INFI +31.40% (closing at $2.72 technical breakout day)
INNT +188.33% ( 2days run; $17.30 closing)
MDGL +10.78%
NVAX +59.40% (Price target raised to $10 FROM $2.25 at B. Riley FBR
NVRO +14.40% ( receives FDA approval for SENZA ll SCS System)
OMER +35.31% (Amid favorable Medicare Policy in Congressional Spending Bill)
PIRS (+20.14%) entered collaboration with SGEN
PTI +54.11% (FDA grants breakthrough therapy)
PTIE +103.15% (Positive Topline for Nasal Abuse
RGNX +26.90% (record high post Q4 '17 earnings report; $37.50 closing*
RKDA +311.23% (low floater with news wheat program breakthrough)
SGMO +14.41% (Collaboration with CELG)
SRNE +17.75% ( Closing at $9.95, FDA approves ZTlido)
TENX +128.45% ( announced publication of a positive pre clinical study of levosimindan* $10.60 closing)
VKTX +14.31% ( strong price of secondary $5 at 11M shares)
VTVT +28.43% ( technical breakout)
ZSAN +24.56% (3/6/18*$9.28 closing; technical run up)
ZSAN +27.25% (3/8* $18.49 closing)
ZSAN +56.57% (3/7* $14.53 closing)
ZSAN +72.20% (3/5* $7.68 closing, patent announcement rally)
ABBV -12.76% ((P2 trial Rova-T disappointing data)
ACAD -20.04% (closing at $24.92, earning report missed)
ADMS (-21.85%) Approval of a competing product from Osmotica
AKRX -38.41% (Fresenius may back out of Akorn deal if probe finds breaches)
ANTH -80.87% (Phase 3 failed)
ARDM (-33.92%) FDA Antimicrobial Drugs Advisory Committee did not rec'd approval
AXON -19.63% ( CEO Dr. Hung & COO stepped down
AXON -56.98% ( intepirdine did not meet primary endpoint
AXSM -35% ( discontinued CREATE-1 trial)
BIIB (-6.60%) Alzheimer's uncertainty result
BLCM (-25.85%) Clinical hold BPX-501
CDTX -24.05% (Stock selling after Phase 2 data update)
CELG --9.04% (closing at $87.12, refusal to file from FDA)
DERM -65.86% (Phase 3 trial failed to meet the co-primary endpoints)
EIGR (-49.38%) failed 2 LIBERTY to meet primary endpoint
EXAS -9.95% (sell off on ASCO abstract)
EYEG -41.54% ( EGP-427 P2B did not meet co- primary endpoints)
INSY -26.31% (+11.23% weekly gain Jan 2-5* despite 1 dy sell off*)
KALA -29.28% Topline result for two phase 3 trials
MDXG (-39.56%) postpones FY17 earning report
OHRP -81.33% data did not meet endpoint
PBYI -28.82% ( receives negative trend vote over MAA for Neratinib)
PTGX -57.17% (discontinue P2b PROPEL study)
PTLA -25.43% (3/1 FDA requires additional randomized trial for Andexxa/ $31.56 closing)
PTLA -6.86% ($44.91 close; receives + CHMP opinion on Andexxa, but negative on Bevyxxa)
SLDB -64.58% (Closing at $9.32,. IGNITE DMD trial put on clinical hold by FDA)
SNSS -42.39% (Delayed Next-gen BTKi due to slow enrollment)
TTPH (-60.41%) IGNITE3 trial did not achieve its co-primary endpoints
VBLT -61.03% (closing at $2.65 after failed phase 3)
VRX -11.41% (closing at $16.39, earning report missed)
Sell the Gap
AIMT -6.02% ( +12.90% intraday high; +25% premarket high; reported positive P3 Palisade trial in Peanut allergy)
ALXN +3.38% (Stock up 11% to $137.88 high from ALXN1210 data0
ARGS +.69% ( +37% after hours trading; licensed PD1 checkpoint inhibitors)
BOLD -23.30% in 2 days ( giving up all its gain after AT132 P1/2 data release)
KDMN -21.28% ( KD025 data - +10.53% intraday; +15.7% after hours, $3.81 closing)
NVAX +4.61% (3/1* +26% intraday* reports positive flu vac* $2.27 closing)
RETA -.04% ( +7.64% intraday; +8.7% after hours; says patients treated w/ Bardoxolone experienced benefits on their kidneys)
Reversal off Lows
BHVN -7.27% (from -20% premarket after P3 migraine study met endpoints)
DBVT-3.21% (-8% intraday low, in lieu of AIMT + P3 Palisade trial)
GLMD +93% in 2 days ( initially dropped -62% top-line results from the ARRIVE Trial)
KALA +32% bounce in 5 days since initial gap down reaction on P3 result of Topline data

Quarter 4 2017

ADMS +21.01% (*Evercore ISI gives it $85 price target, plus Point72 reported 5.1% passive stake*)
ANAB +101% (reported positive results of P2a ANB020)
ARDX +44.44% (*Tepanor study meets endpoints*)
ARGX +78.8% (+91% weekly gain; ASH'17 data update pn Phase 1/2 clinical trials for AML & CTCL ARGX-110)
BIOC +69.12% (* announces issuance of U.S patent core to BIOC Target Select Assays for ctDNA)
BLUE +17.91% (*ASH '17 data presentation of its Lentiglobin; record high $10bil MC)
CBIO +29.62% (announces acceleration of Phase 1/2 trial of CB 2679d/lSU304 in individuals w/ Hemophilia B)
CLSN +123.33% (*weekly gain, rallies on aanouncement of final clinical & translational research data from its OVATION Study*)
ECYT +307.8% (*weekly gain on completion of an exclusive worldwide license of PSMA-617 from ABZ GmbH*)
FLXN +23.78% (*weekly gain, FDA approved its Zilretta drug*)
INFI +123.35% (Wells Fargo Upgrade to $5PT,cites IPI-549 potential*)
MDGL +88.29% (met primary endpoint in a P2 NASH study for MGL-3196*)
MNKD +131.80% (*weekly gain, on FDA update on Affreza prescribing information*)
MRNS +39.58% (*sympathy move with MDGL*)
ONCS +60.00% updated data from P2 OMS I-102 .
OTIC +83.04% reporting 'positive' Phase 3 Otividex trial
PTI +161.28% (*positive data from PTI-428,PTI-801,& PTI-808*)
RVNC +33.65% (RT002 met primary and secondary endpoints)
SAGE +54.25% (positive trial results in postpartum depression)
VKTX +35.10% weekly gain (* sell the gap initial reaction, next 2 days +45% bounce, rally in sympathy move w/ MDGL*)
VTVT +44.82% weekly gain (rallies on increase stake of Ron Perelman)
ACOR -39.72% (tozadenant for Parkinson's groups, five of which were fatal)
ACRX -59.81% (*receives CRL from FDA for DSUVIA*)
CALA -41% in two days. (CB-839 combo fail to impress investors at SITC)
FPRX -40.90% (*tanked on Cabiralizumab abstract presented on SITC*)
GALT -30.65% (P2b NASH-CX trial update)
GBT -14.24% (ASH '17 presented treatment for SCD #Voxelotor drug.
JUNO -14.33% ~ initial reaction, -23.82% for the week* (ASH '17 reported additional data from TRANSCEND study)
JUNO -14.34% (*ASH '17 presented addtl data from TRANSCEND study of JCAR017*)
ONCE -34.97% (*ASH '17 presented SPK-8011; -50% intraday low; 52weeks low print*)
RARX -37.32% (* Met Primary Endpoint for Phase 2 RA101495, sold off on efficacy inferior to ALXN1210*
RDHL -29.60% offering of 4,090,909 American Depositary Shares, public offering price of $5.50 per ADS for gross proceeds to $22.5m
SYRS -31.69% (*ASH '17 presented new preclinical data on SY-1365; intraday low -49%)
Sell the Gap
AIMT +28.37% from +56% or 39.90 premarket high*; DVBT PH3 failure in peanut allergy is AIMT gain*
VKTX +9.12% (*+39% intraday, +52% premarket, sympathymove with MDGL on positive P2 data of MGL-3196*; after 2 days total rally +45%*)
VSTM -16.86% (+57% premarket; +10.6% intraday; ASH '17 released PH3 result of DUO*)
Reversal off Lows
BHVN -4.86% (*-28.70% intraday low, TRIGRILUZOLE Phase2/3 no difference from Placebo
GALT unchanged* weekly performance (*initial reaction is -32% 2 days rally brought it back to unchanged for the week*)
NKTR +5.71% (-5% premarket low, INHALE Ph3 study did not meet endpoint)

Quarter 3 2017

AKTX +51.20% (*Plans to advance COVERSIN towards PH3)
ALNY +49.32% (meets all endpoint for APOLLO Phase3 of PATISIRAN*)
CLSN +123.33% (*weekly gain, rallies on aanouncement of final clinical & translational research data from its OVATION Study*)
ZGNX +172.23% (*Meets endpoint ZX008 of Phase 3 trial for Dravet syndome*)
ZYNE +34.19% *ZYN002 gel meets primary endpoint in Phase 2 Fragile X syndrome trial.*
AXON -72.47% (*Failed Phase 3 MINDSET study*)
GNCA -72.40% (*Ceased GEN 003 and shifted focus towards Immunocology*)
ICPT -35.09% (FDA safety announcement on OCALIVA*)
VSAR -85.42% (*Phase 3 of SOMAVARATAN did not meet primary endpoint*)
Sell the Gap
NBRV +29.30% from +105% intraday high* (rallies on LEAP 1 trial)
Reversal off Lows
PTCT +8.05% (*-23% intraday low to positive territory*)

Please select phase first
Disclaimer! This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that will not be held responsible and accountable for any losses you may incur using our Biotech Data Calculator. Please consult your own financial adviser before executing trades.